ABSTRACT
Neutrophil release of cytoplasmic granules containing antimicrobial agents is a critical component of innate immunity. Neutrophils are widely implicated in other disease responses yet the overall extent of the neutrophil contribution to human health and disease is incompletely characterized. To explore this further, we leveraged publicly available genetic data to conduct a Mendelian randomization phenome-wide association study (MR-PheWAS) of neutrophil traits and 14,983 outcomes.
Genetic proxies for neutrophil count, granularity, and serum myeloperoxidase were linked to 146 outcomes. Higher neutrophil count was associated with lower body weight, reduced obesity risk, and increased vascular activation markers but not with atherosclerosis. Elevated neutrophil count was robustly linked to Alzheimer’s disease and neutrophil granularity with gut microbiota abundance and dental pathology.
Our findings reveal the diverse roles of neutrophils extending beyond pathogen defense and underscore the potential for MR-PheWAS in identifying novel neutrophil-related pathophysiology.
Summary sentence Neutrophils, essential for immunity, also influence other aspects of health, as shown in our MR-PheWAS study linking genetic proxies for neutrophil traits to 146 outcomes, including obesity, Alzheimer’s disease, endothelial activation markers and gut microbiota.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Wellcome Trust GW4 Clinical Academic Training Programme for Health Professionals to KF [227485/Z/23/Z] and NC [225541/Z/22/Z]. BA is funded by MRC grant MR/R02149X/1. KB is funded by an NIHR Academic Clinical Lectureship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis used GWAS summary data only, therefore no additional ethical approval was required. Approval was obtained by the original GWAS studies by their appropriate ethics review boards: see details in the source GWAS publications.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of interest: The authors declare no competing financial interests.
Data availability
R scripts used for the analysis are available via GitHub [https://github.com/kateburley/Neutrophil_PheWAS]. Harmonized summary data for all SNPs included in this analysis and full MR results are available through the University of Bristol Research Data Repository.
